Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
183 hedge funds and large institutions have $3.15B invested in Medicines Co in 2015 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 76 reducing their positions, and 25 closing their positions.
409% more call options, than puts
Call options by funds: $98.8M | Put options by funds: $19.4M
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
50% more capital invested
Capital invested by funds: $2.1B → $3.15B (+$1.05B)
48% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 25
6% more funds holding
Funds holding: 172 → 183 (+11)
24% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$271M |
| 2 |
AA
Antipodean Advisors
New York
|
+$85.6M |
| 3 |
Millennium Management
New York
|
+$71M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$69.1M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$79.4M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$35.5M |
| 3 |
PC
PointState Capital
New York
|
-$22.3M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$21.8M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
201
Spark Investment Management
New York
| – | -$423K | -14,800 | Closed |
|
202
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$385K | -13,440 | Closed |
|
|
HCM
203
Highbridge Capital Management
New York
| – | -$333K | -11,649 | Closed |
|
|
NIT
204
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$332K | -11,600 | Closed |
|
|
CIM
205
CIM Investment Management
Pittsburgh,
Pennsylvania
| – | -$261K | -9,125 | Closed |
|
206
HighTower Advisors
Chicago,
Illinois
| – | -$208K | -7,259 | Closed |
|
|
TRCT
207
Tower Research Capital (TRC)
New York
| – | -$43K | -1,498 | Closed |
|
208
Walleye Trading
New York
| – | -$20.7K | -589 | Closed |
|
209
Nomura Holdings
Tokyo,
Japan
| – | -$3K | -100 | Closed |
|
MDCO Hedge Fund Activity: Q3 2015 in Review
183 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2015, worth a combined $3.15B — up 50% from $2.1B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MDCO positions and 25 closed out — a net gain of 12 holders — while 58 added to existing stakes and 76 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $271M. The largest seller was T. Rowe Price Associates, cutting an estimated $79.4M.
- 183 institutional investors held Medicines Co (MDCO) as of Q3 2015, up from 172 in Q2 2015.
- Funds reported $3.15B of Medicines Co stock for Q3 2015, up 50% quarter-over-quarter.
- 37 funds opened new Medicines Co positions in Q3 2015 and 25 closed out, a net change of +12 holders.
- The largest Medicines Co buyer in Q3 2015 was Fidelity Investments, an estimated $271M added.
- The largest Medicines Co seller in Q3 2015 was T. Rowe Price Associates, an estimated $79.4M sold.
Based on aggregated 13F filings for Q3 2015.